NuMedii

NuMedii will use its AI technology in combination with single-cell data to identify biomarkers and therapeutics for idiopathic pulmonary fibrosis.

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

Using funds from the California precision medicine initiative, the group will use its bioinformatics expertise to match patients to treatments in pediatric clinical trials.

The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.

In April, Butte became director of UCSF's Institute for Computational Health Sciences and executive director of clinical informatics for UC Health Sciences and Services. 

Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Atul Butte, an associate professor in Stanford University's School of Medicine, was recently named as one of 13 Open Science Champions of Change by the White House's Office of Science and Technology Policy for his efforts to use and support open data in biomedical research.

NEW YORK (GenomeWeb News) – NuMedii announced today that it has raised $3.5 million in a Series A funding round led by Claremont Creek Ventures and Lightspeed Venture Partners with participation from Life Science Angels and others.

NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

By Uduak Grace Thomas
NuMedii, a Stanford University spinoff, hopes to make its bread and butter by partnering with traditional and specialty pharmaceutical companies to identify new indications for existing medicines.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.